Zogenix, which recently launched Sumavel DosePro, a needle-free injectable migraine treatment, raised $56 million by offering 14 million shares (versus 6 million shares as originally planned) at $4, a sharp 69% discount to its proposed range of $12 to $14. Zogenix, which has a market capitalization of $124 million at the IPO price, plans to list on the NASDAQ under the symbol ZGNX on Tuesday. Wells Fargo Securities and Leerink Swann acted as lead managers on the offering.
